Press release
The first patient to be injected with an RNA based anti-cancer vaccine
The possibilities of RNA therapeutics have never been so exciting! Moderna Therapeutics have just announced that their first patient has been injected with their potentially ground-breaking RNA based anti-cancer vaccine. This individualised medicine has been designed to assist the immune system of each patient to recognise and attack the cancer. http://bit.ly/2ilVA6C
Want to learn more about RNA therapeutics and their potential to treat cancer?
Explore how miRNases can target lyphosarcoma cells with Elena Bichenkova from Manchester University. She will discuss how novel peptide-olognucleotide biconjugates can silence miR-21 in lymphosarcoma cells as a potential intervention for cancer and how intelligent ant-cancer therapeutics are being developed against oncogenic microRNAs. Elena will also present key challenges in the traditional drug discovery and development (DDD) process, where she will highlight some emerging opportunities in attempt to overcome the key issues.
Day 1 | @12.20 | miRNases: Novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells
Elena Bichenkova, Senior Lecturer in Medicinal Chemistry, Manchester University
You can also discover opportunities and challenges of developing microRNA based oligonucleotide therapeutics with Ekkehard Leberer. He will illustrate the generation of an anti-fibrotic oligonucleotide drug targeting microRNA-21, which has been implicated in multiple organs with fibrosis and cancer. Ekkehard will also present, how MicroRNAs regulate by the mechanism of RNA interference (RNAi) biochemical pathways involved in human diseases.
Keynote Address: Day 1 | @11:40 | MicroRNA Therapeutics: Opportunities and Challenges for Targeting the Pathways of Human Disease
Ekkehard Leberer, Senior Director, Sanofi
SMi’s RNA Therapeutics will be bringing a global presence from MHRA, The RNA Institute, MiNA Therapeutics, AstraZeneca R&D, GSK, Sanofi, CureVac and more. With an agenda full of exciting and new approaches, examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches and patenting RNA Therapeutics. www.therapeutics-rna.com/opr
For those looking to attend there is currently a £200 early-bird saving, ending November 30th.
Further information is available at: www.therapeutics-rna.com/opr
SMi presents the 9th Annual Conference:
RNA Therapeutics
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Website: www.therapeutics-rna.com/opr
Sponsored by: ChemGenes | Phion Therapeutics
---end---
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
1
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The first patient to be injected with an RNA based anti-cancer vaccine here
News-ID: 833355 • Views: …
More Releases from SMi Group
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK.
The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines.
Darren Green, Director of Computational Chemistry at GSK will be chairing at…
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety.
SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA.
The 2022 Conference theme is…
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022.
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering…
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022.
Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022.
This event will convene on February 9th – 10th 2022,…
More Releases for RNA
CD Formulation Launches Custom Circular RNA Synthesis Service to Accelerate RNA …
CD Formulation introduces a customizable circRNA synthesis service, delivering high-quality, stable circRNAs for therapeutics, vaccines, and gene research, supported by advanced design and QC processes.
CD Formulation, a leading provider of advanced small nucleic acid synthesis [https://www.formulationbio.com/nucleic-acid/custom-small-nucleic-acid-synthesis.html] solutions, is proud to announce the launch of its fully customizable circular RNA (circRNA) synthesis service. This new service addresses the growing need for stable, non-immunogenic RNA molecules for therapeutic development, vaccine research, and…
Self-Amplifying RNA Synthesis Market Gains Traction as Biotech Firms Embrace Sca …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Self-Amplifying RNA Synthesis Market- (By Product & Service (Products (Enzymes & Reagents, Premade saRNA, Others), Custom Synthesis Services), By Application (Therapeutics Development (Oncology, Infectious Diseases, Others), Biomedical Research), By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic,…
RNA Extraction and RNA Purification Market: Growth, Trends & Competitive Landsca …
The global RNA Extraction and RNA Purification Market is expected to grow at 6.3% CAGR from 2025 to 2032.
This Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
• 70% efforts of Primary Research
• 15% efforts of Secondary Research
• 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited…
RNA Targeting Small Molecules Therapeutics Market: Exponential Growth with Risin …
Estimations Predict a CAGR of 29.8% by 2029 in Global RNA Targeting Small Molecules Therapeutics Market Boosted by Precision Medicine, RNA Biomarker Identification and RNA Genetic Manipulation
What Is The Projected Market Size of The Global RNA Targeting Small Molecules Therapeutics Market And Its Growth Rate?
• The market will grow from $6.1 billion in 2024 to $7.87 billion in 2025 at a compound annual growth rate (CAGR) of 28.9%.
• Expected exponential…
Global DNARNA Extraction Kit Market by Type (Cell-free DNA (cfDNA), Sequence-spe …
"DNARNA Extraction Kit Market" is segmented by Company, Region (country), By Type, Application, stakeholders and other participants. This report provides an analysis of revenue and forecast across Type and Application segments for 2023-2032.
The market for DNARNA Extraction Kits has been thoroughly researched via primary and secondary sources to produce this research study. Along with a competitive analysis of the market, segmented by application, type, and geographical trends, it offers a…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
